Recent Updates
Recently added Catalysts
AIM Positive Sentiment Score: 70/100

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Friday, March 22, 2024 1 min read
Key Takeaway: AIM ImmunoTech has released the latest segment of its CEO Corner, featuring insights from CEO Thomas Equels. In this segment, Equels discusses the company's business outlook and the opportunities presented by AIM's innovative therapies. The segment is part of the Virtual Investor Lunch Break series and is accessible on the company's website. AIM ImmunoTech focuses on developing treatments for cancers and immune disorders, with their lead product being Ampligen®.

Market Sentiment Analysis

POSITIVE FACTORS

  • The CEO provided a detailed corporate overview and business outlook.
  • The segment highlights AIM's ongoing commitment to immuno-pharmaceutical advancements.
  • Ampligen® is positioned as a first-in-class investigational drug with potential broad applications.

Full Press Release Details

OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, provided a corporate overview, a business outlook and discussed the AIM opportunity as part of the Virtual Investor Lunch Break series.
The CEO Corner segment is now available here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Tags

Frequently Asked Questions

What recent announcement did AIM ImmunoTech make?

AIM ImmunoTech published the latest CEO Corner segment on its website.

Who is the CEO of AIM ImmunoTech?

Thomas Equels is the Chief Executive Officer of AIM ImmunoTech.

What is AIM ImmunoTech's main focus?

The company focuses on developing therapeutics for cancer, immune disorders, and viral diseases.

What is AIM ImmunoTech's lead product?

Their lead product is Ampligen® (rintatolimod), an investigational drug.

How can I learn more about AIM ImmunoTech?

Visit aimimmuno.com or connect on X, LinkedIn, and Facebook.

Tags: AIM Viatris Investor Conferences Healthcare immunotherapy Ampigen cancer treatment Thomas Equels
Last updated: Mar 22, 2024